文献速递真菌感染

脑脊液半乳甘露聚糖检测诊断中枢神经系统曲霉病:一项诊断试验准确性系统评价与Meta分析

Cerebrospinal fluid galactomannan detection for the diagnosis of central nervous system aspergillosis: a diagnostic test accuracy systematic review and meta-analysis.
PubMed 文献 · Clin Microbiol Infect · 2024-05-27

该系统评价与Meta分析纳入8项研究共342例患者,评估脑脊液半乳甘露聚糖诊断中枢神经系统曲霉病的准确性。汇总敏感度为69.0%(95%CI 57.2-78.7%),特异度为94.4%(95%CI 82.8-98.3%)。脑脊液半乳甘露聚糖是高度特异但敏感度不足的检测,可作为中枢神经系统曲霉病诊断的组成部分。

要点

  • 脑脊液半乳甘露聚糖诊断中枢神经系统曲霉病的汇总敏感度为69.0%,特异度为94.4%。
  • 采用半乳甘露聚糖 cut-off 1.0 可提高诊断敏感度。
  • 纳入研究少、无前瞻性研究且偏倚风险高是本研究局限。

核心结论

  • 脑脊液半乳甘露聚糖是高度特异但敏感度不足的检测,可作为中枢神经系统曲霉病诊断的组成部分。

研究设计与样本

  • 系统评价与Meta分析,检索MEDLINE、Embase、Web of Science和Scopus自建库至2023年2月24日,纳入前瞻性和回顾性、1组和2组设计、使用任何半乳甘露聚糖检测脑脊液诊断中枢神经系统曲霉病的研究,共纳入8项研究342例参与者。

主要发现

  • 脑脊液半乳甘露聚糖诊断中枢神经系统曲霉病的汇总敏感度为69.0%(95%CI 57.2-78.7%),汇总特异度为94.4%(95%CI 82.8-98.3%)。
  • Meta回归显示半乳甘露聚糖 cut-off(p=0.38)、EORTC/MSGERC标准版本(p=0.48)或参照标准定义为确诊加临床诊断还是仅确诊(p=0.48)均未能解释观察到的异质性。
  • 分析所用EORTC/MSGERC参照标准(如2002版 vs 2008版)或是否纳入儿童患者,未显示亚组效应。
  • 采用半乳甘露聚糖 cut-off 1.0 以及排除高偏倚风险和1组设计研究后,诊断敏感度提高。

关键数值与推荐

  • 参照标准为欧洲癌症研究与治疗组织及真菌研究组教育与研究联盟(EORTC/MSGERC)诊断标准或等效标准。
  • 采用双变量限制性最大似然估计随机效应Meta分析,并以森林图和汇总受试者工作特征曲线总结。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 纳入研究少。
  • 无前瞻性研究。
  • 偏倚风险高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cerebrospinal fluid (CSF) galactomannan is an adjunctive test for central nervous system (CNS) aspergillosis diagnosis with unclear diagnostic test characteristics. OBJECTIVES: To evaluate the diagnostic test characteristics of CSF galactomannan in CNS aspergillosis. METHODS: Systematic review and meta-analysis. DATA SOURCES: MEDLINE, Embase, Web of Science, and Scopus, from inception to 24 February 2023. STUDY ELIGIBILITY CRITERIA: Prospective and retrospective studies with 1-group and 2-group designs using any galactomannan assay on CSF to diagnose CNS aspergillosis. PARTICIPANTS: Adult and/or paediatric patients with CNS aspergillosis. TEST(S): Galactomannan testing on CSF specimens. REFERENCE STANDARD: European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium (EORTC/MSGERC) diagnostic criteria, or equivalent. ASSESSMENT OF RISK OF BIAS: QUADAS-2 assessment in duplicate. METHODS OF DATA SYNTHESIS: Bivariate restricted maximum likelihood estimation random-effects meta-analysis, summarized using forest and summary receiver operating characteristic plots; bivariate meta-regression models to investigate heterogeneity; and subgroup and sensitivity analyses to explore subgroup effects and methodologic choices (PROSPERO registration: CRD42022296331; funding: none). RESULTS: We included eight studies (n = 342 participants). The summary estimates of CSF galactomannan sensitivity and specificity were 69.0% (95% CI, 57.2-78.7%) and 94.4% (95% CI, 82.8-98.3%), respectively. Using meta-regression, galactomannan cut-off (p = 0.38), EORTC/MSGERC criteria version (p = 0.48), or whether the reference standard was defined as both proven and probable or only proven aspergillosis (p = 0.48) did not explain observed heterogeneity. No subgroup effects were demonstrated by analysing the EORTC/MSGERC criteria reference standard used (e.g. 2002 vs. 2008 definitions) or whether paediatric patients were included. Diagnostic sensitivity was improved using a galactomannan cut-off of 1.0, and by excluding high risk of bias and 1-group design studies. DISCUSSION: CSF galactomannan is a highly specific but insensitive test for use as a component of CNS aspergillosis diagnosis. Few included studies, no prospective studies, and a high risk of bias are study limitations.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Komorowski AS, Hall CW, Atwal S, et al. Cerebrospinal fluid galactomannan detection for the diagnosis of central nervous system aspergillosis: a diagnostic test accuracy systematic review and meta-analysis. Clin Microbiol Infect. 2024. PMID: 38810927. doi:10.1016/j.cmi.2024.05.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。